-
Mashup Score: 0Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 8 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 16Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease - 8 month(s) ago
AbstractAims. Finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, improves cardiovascular (CV) and kidney outcomes in patients with ty
Source: academic.oup.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @SABOURETCardio: Finerenone efficacy in patients with #CKD #T2D #ASCVD #T2D https://t.co/q3H5ND6dvR
-
-
Mashup Score: 48Association of Coronary Artery Calcium Detected by Routine Ungated CT Imaging With Cardiovascular Outcomes: - 8 month(s) ago
Abstract Background Coronary artery calcium (CAC) is a strong predictor of cardiovascular events across all racial and ethnic groups. CAC can be quantified on nonelectrocardiography (ECG)-gated com…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Incidental #CAC≥100 quantified on non-gated CT using an #AI algorithm was assoc w/ worse #CVD & mortality outcomes, beyond traditional risk factors & PCE. This suggests value in population-wide opportunistic screening for #ASCVD w/ incidental CAC https://t.co/hz3jdov4ks #JACC… https://t.co/jRsPS5eHYK https://t.co/i8lniex9sX
-
-
Mashup Score: 0Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 8 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet-
📝 What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease? #CME #MedX #ASCVD 📍 https://t.co/A8vRTCrXGb https://t.co/kYcBzwp76f
-
-
Mashup Score: 7
Background Platelet‐poor plasma serotonin levels are associated with adverse cardiovascular outcomes. Although plasma serotonin levels increase in chronic kidney disease, the cardiovascular implica…
Source: www.ahajournals.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
In this study, @DanEdmonston and colleagues show plasma serotonin levels are linked to #CVD outcomes in #CKD: High levels associated with LVH, undetectable levels with heart failure and #ASCVD events. #AHAJournals @DukeKidney https://t.co/MkKIx7qF62 https://t.co/7BDyshfgr8
-
-
Mashup Score: 7
The Multilingual ASCVD Risk Estimator is a simplified web-based version of the ASCVD Risk Estimator Plus app that provides clinicians with an efficient way to calculate a patient’s estimated 10-year ASCVD risk, optimal risk and lifetime risk.
Source: www.acc.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
DYK the Multilingual ASCVD Risk Estimator is available in 6 languages❓ Download it now and use it to efficiently calculate a patient’s estimated 10-year #ASCVD risk, optimal risk & lifetime risk. Visit the ACC Booth to learn more! https://t.co/WJK4hZnEFm #ESCCongress https://t.co/YuInvpV254
-
-
Mashup Score: 41Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society - 8 month(s) ago
Abstract. Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despi
Source: academic.oup.comCategories: Expert Picks, Latest HeadlinesTweet-
Our EAS position paper on women, lipids & #ascvd published just in time for #ESCCongress 💃🏻 Sex differences in traditional risk factors 💃🏻 Sex specific risk factors 📢Call to action in our care of women across lifespan 🎯 Women are 51% of population https://t.co/jtDsADa6TJ https://t.co/B86zWMuIIn
-
-
Mashup Score: 0Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 9 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Latest Headlines, NeurologyTweet-
📝 What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease? #CME #MedX #ASCVD 📍 https://t.co/RqQBNzdXyJ https://t.co/TV53fCOvEr
-
-
Mashup Score: 8Back to the Future: Revitalizing the Role of Cholesteryl Ester Transfer Protein (CETP) Inhibition for CV Risk Reduction - 9 month(s) ago
What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease (ASCVD)?
Source: www.medscape.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
📝 What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease? #CME #MedX #ASCVD #ESCCongress 📍 https://t.co/H8MEqt6tja https://t.co/TfqqpLIneE
-
📝 What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease? #ESCCongress 📍 https://t.co/LolFrZXdS7 https://t.co/K81V7Pxsrf
-
-
Mashup Score: 1Are Fish Oils on the Hook for AF Risk? - 9 month(s) ago
Some studies of fish oil supplements have shown a higher risk for atrial fibrillation with marine omega-3 fatty acids. Is it real? What are the implications for patients taking these capsules?
Source: www.medscape.comCategories: Healthcare Professionals, Latest HeadlinesTweet-
Are #FishOils on the Hook for AF Risk? https://t.co/jRUgn48SL7 via @medscape #AtrialFibrillation #CVD #ASCVD Interesting, insightful, and important assessment, but @drjohnm has avoided possible benefits of #fishoil on other aspects of human health, e.g. #NervousSystem. #Brain… https://t.co/h8WriCh8jF
-
📝 What is CETP inhibition, and can it be the answer to further lowering risk in patients with atherosclerotic cardiovascular disease? #CME #MedX #ASCVD 📍 https://t.co/AecA2yf2zH https://t.co/e7uMVNDD93